Loading
The enzyme that makes androgens in the testes, the adrenal glands and prostate tumours themselves. Abiraterone blocks it, cutting androgen production below what castration alone achieves. This dossier gathers the 2 products (0 approved), 2 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Cytochrome P450 enzyme of the adrenal cortex, testis and prostate cancer cells; the rate-limiting step of androgen synthesis from pregnenolone.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Prostate cancer | nearly all% | Androgen-driven at diagnosis; abiraterone acts on androgen synthesis in almost every prostate cancer, resistance develops later | cancer.gov |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Withdrawn or failed |
|---|---|
| Small molecule 2 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
ARMOR3-SV NCT02438007 | 3 | Negative | Metastatic castration-resistant prostate cancer with AR-V7 messenger RNA detectable in circulating tumour cells, in men naive to enzalutamide, abiraterone and chemotherapy: galeterone against enzalutamide, open-label, with radiographic progression-free survival as the primary endpoint | Closed early after 38 of a planned 148 men were randomised; AR-V7 prevalence 8 percent (95 percent confidence interval 6 to 10) among 953 prescreened men. PSA50 response 13 percent with galeterone against 42 percent with enzalutamide. Galeterone development stopped. | |
ELM-PC 4 NCT01193244 | 3 | Negative | Progressive metastatic castration-resistant prostate cancer with no previous chemotherapy: orteronel 400 mg with prednisone 5 mg twice daily against placebo with prednisone, with two primary endpoints, radiographic progression-free survival and overall survival | Median radiographic progression-free survival 13.8 against 8.7 months (hazard ratio 0.71, 95 percent confidence interval 0.63 to 0.80, p<0.0001) but overall survival 31.4 against 29.5 months (0.92, 0.79 to 1.08, p=0.31); development stopped. |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"CYP17A1" OR ABSTRACT:"CYP17A1" OR TITLE:"17-alpha-hydroxylase/17,20-lyase" OR ABSTRACT:"17-alpha-hydroxylase/17,20-lyase") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CYP17A1 (17-alpha-hydroxylase/17,20-lyase), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/cyp17a1.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/cyp17a1.json. Licence CC BY-NC 4.0.